Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine Tartrate Nanoemulsion in Ocular GVHD
NCT03591874Phase 3Terminated
- Sponsor
- Ocugen
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brimonidine in ocular graft-versus-host disease (oGVHD), sponsored by Ocugen. Started Dec 2018; status: terminated.
02
Drugs
brimonidine
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT03591874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591874.